

Orexigen Therapeutics Reports Preclinical Results Showing Contrave

SAN DIEGO--(BUSINESS WIRE)--Oct 23, 2007 - Orexigen(TM) Therapeutics, Inc. (NASDAQ: OREX), a biopharmaceutical company focused on the treatment of central nervous system (CNS) disorders including obesity, today presented the results of a preclinical study that further supports the Company's understanding of an aspect of the mechanism of action of Contrave(TM), one of its two late-stage obesity drug candidates.

The drugs act in a part of the brain where food reward pathways are located;

-- The combination directly increased firing of neurons associated with reduction in food intake and satiety.

The data were disseminated in a poster presentation* at The Obesity Society's Annual Scientific Meeting (NAASO) being held in New Orleans, October 20-24, 2007.

"We originally theorized that the combination of bupropion and naltrexone, the components of Contrave, would stimulate proopiomelanocortin (POMC) neuronal firing which would lead to sustained weight loss. These new findings indicate that Contrave may also modulate food cravings through its effect on reward pathways," said Orexigen founder and Chief Scientific Officer, Michael Cowley, Ph.D. "We believe this aspect of Contrave's mechanism of action may have the potential to differentiate it from other pharmaceutical therapies available or in development for the treatment of obesity."

One study examined the effects of bupropion, naltrexone and the combination of bupropion plus naltrexone in both lean and obese mice. In lean mice, treatment with bupropion, naltrexone or the combination resulted in a 34%, 67% and 77% reduction of food intake, respectively. In obese mice, treatment with bupropion, naltrexone or the combination resulted in a 27%, 49% and 94% reduction of food intake, respectively. The interaction between bupropion and naltrexone appeared more potent in obese mice than in lean mice.

A separate study examined the effects of bupropion, naltrexone or the combination of bupropion plus naltrexone when they were selectively administered to the ventral tegmental area (VTA), a part of the brain that is often described as the center of "the reward pathway". This is the region of the brain that determines whether an environmental stimulus is rewarding or aversive. The combination of bupropion plus naltrexone in the VTA caused a statistically significant, synergistic reduction of food intake suggesting a possible connection to the behavioral aspects of obesity.

Contrave employs a proprietary formulation of two CNS molecules, bupropion and naltrexone, that have been independently approved by the US Food and Drug Administration in other indications. Orexigen chose these two constituent drugs based on the results of a proprietary screening model and the Company's understanding of circuitries in the brain that regulate appetite and energy balance. The unique combination of these molecules is designed to provide more clinically meaningful weight loss for patients by both initiating weight loss and sustaining it over a longer period of time.

About Orexigen Therapeutics

Orexigen Therapeutics, Inc. is a biopharmaceutical company focused on the development of pharmaceutical product candidates for the treatment of central nervous system disorders including obesity. Orexigen's lead combination product candidates targeted for obesity are Contrave(TM), which is in Phase III clinical trials, and Empatic(TM), which is in the later stages of Phase II development. Both product candidates are designed to take advantage of the Company's understanding of how the brain appears to regulate appetite and energy expenditure, as well as the mechanisms that come into play to limit weight loss over time. Each product candidate is designed to act on a specific group of neurons in the central nervous system with the goal of achieving appetite suppression and sustained weight loss. Further information about the Company can be found at <http://www.Orexigen.com>.

Forward-Looking Statements

Orexigen cautions you that statements included in this press release that are not a description of historical facts are forward-looking statements. Words such as "believes," "anticipates," "plans," "expects," "indicates," "will," "intends," "potential," "suggests," "assuming" and similar expressions are intended to identify forward-looking statements. These statements are based on Orexigen's current beliefs and expectations. These forward-looking statements include statements regarding the science of the mechanism of action of Contrave and the potential to effectively treat obesity with Contrave. The inclusion of forward-looking statements should not be regarded as a representation by Orexigen that any of its plans will be achieved. Actual results may differ from those set forth in this release due to the risk and uncertainties inherent in Orexigen's business, including, without limitation: the potential that earlier preclinical studies and clinical trials may not be predictive of future results; the potential for adverse safety findings relating to Contrave to delay or prevent regulatory approval or commercialization, or result in product liability claims; Orexigen and its licensors may

not be able to obtain, maintain and successfully enforce adequate patent and other intellectual property protection of its product candidates; and other risks described in Orexigen's filings with the Securities and Exchange Commission (SEC), including those detailed under the heading "Risk Factors" in Orexigen's Quarterly Report on Form 10-Q for the quarter ended June 30, 2007 filed with the SEC on August 10, 2007. You are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date hereof, and Orexigen undertakes no obligation to revise or update this news release to reflect events or circumstances after the date hereof. All forward-looking statements are qualified in their entirety by this cautionary statement. This caution is made under the safe harbor provisions of Section 21E of the Private Securities Litigation Reform Act of 1995.

For more than 20 years, executives like you have relied on Engel Publishing Partners for the business, marketing, and clinical research information needed to make informed business decisions. InfoPass gives you access to an array of integrated information services information that is critical to your success and the success of your organization.

Fatty liver formation of many reasons, and obesity is one common factor. Obesity associated with many diseases, including hypertension, diabetes, hyperlipidemia, and fatty liver hyperuricemia, these chronic diseases with Taiwanese in the ten leading causes of death is heart disease, stroke and certain cancers related to obesity caused as a result of some disease medication for many years did not improve, but must make up its mind heart slimming success, these diseases are no more of the drug. Visibility maintaining ideal body weight, diet and exercise should be initiated to promote good health.

The so-called obesity is the excessive accumulation of body fat, which led to the health of the affected diseases.n

R due to the above-mentioned methods have failed when used, and the obvious complications of the surgery are now commonly used interval of stomach and gastric bypass operation, the latter domestic rarely used.

Most obesity is a multi-factor, and easy to relapse of chronic diseases, and other chronic diseases as it is very difficult to have the so-called cure, but in addition to surgery and very low calorie diet, the process is usually slow (0.5 to 1 kg / week), weight loss than the weight back much easier and faster. Successful weight loss is not to achieve the desired weight, but to reduce at least 5% of body weight, and to maintain for more than one year, so long-term behavioral therapy is necessary, as long as reduce 5-10% of body weight, health situation will be greatly improved.

About the Author

From www.medadnews.com:

Set a weight loss goal, your weight loss goal, goals for weight loss, goals, weight.

Give yourself regular small rewards for achieving your diet, exercise and weight loss goals. Earning several small rewards is typically more motivating.

Proactol Free Weight Loss Goals Ebook. Proactol Free Weight Loss Goals Ebook. Proactol Free Weight Loss Goals Ebook. Proactol Free Low Fat Recipe.

Learn why having specific weight loss goals, in addition to more specific advice on how to eat healthier and how much more active.

Metabolic Research Center is a national weight management company helping people reach and maintain their weight loss goals. We are holistic.

Weight loss goals in obesity from Nutrition Research Newsletter in Array provided free by LookSmart.

Web sites that provide a visual image you can wrap your mind around can be motivational for dieters. Seeing your body at your ideal weight.

Learn the facts about weight loss, health, nutrition and fitness. Setting fitness and weight goals and making a lifestyle change will put you on the.

Source: <http://www.products herbal.com>